Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|January 26, 2018
Metrohm USA Opens New Headquarters in Florida
Author(s)Pharmaceutical Technology Editors
The company relocated its headquarters to Riverview, Florida.
Advertisement
Metrohm USA announced the opening of its new United States headquarters in Riverview, Florida on Jan. 15, 2018. The 90,000-ft2 building includes training facilities for employees and clients, application development laboratories, technical and customer support areas, and a 25,000-ft2 warehouse.
“Metrohm’s dedication to the people that use our instruments and those who support them make us who we are as a company. This new facility demonstrates our commitments as we invest in providing our customers with innovative training facilities and our employees with modern and collaborative work areas,” says Edward Colihan, president and CEO of Metrohm USA, in a company press release.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement